‘Ozempic’ for Pets on the Horizon as New Drug Trial Aims To Tackle Feline Obesity

A new weight-loss treatment for pets, using the same class of drugs as popular human medications like Ozempic and Wegovy, is now being tested in cats.The San Francisco-based company OKAVA Pharmaceuticals has launched the world’s first clinical trial of a GLP-1 therapy for pets. The study, called MEOW-1, involves administering an “ultra-long acting” implant to overweight cats to help them shed pounds. The first feline has already been successfully dosed.The implant, named OKV-119, is a small device inserted under the skin during a routine vet visit. It is designed to deliver a continuous dose of a GLP-1 receptor agonist medication for up to six months, eliminating the need for daily or weekly injections.According to the company, the technology could have “profound” implications for treating common pet ailments like diabetes, kidney disease, and obesity while also promoting healthy aging and longevity.The CEO of OKAVA, Michael Klotsman, said the drug aims to offer a new solution beyond traditional diet and exercise. “Caloric restriction, or fasting, is one of the most well-established interventions for extending lifespan and improving metabolic health in cats,” he said in a press release.“But it’s also one of the hardest to maintain. OKV-119 is designed to mimic many of the physiological effects of fasting — improved insulin sensitivity, reduced fat mass and more efficient energy metabolism — without requiring significant changes in feeding routines or disruption of the human-animal bond that often centers around food,” Mr. Klotsman said.The issue of pet obesity is widespread. Experts estimate that roughly six in 10 cats in the United States are overweight. The epidemic is a primary driver behind the rising rates of diabetes in both cats and dogs.“In veterinary medicine for the last 100 years, the only prescription we had was feed less, exercise more, and that just doesn’t work for all types of obesity,” Dr. Ernie Ward, a leading pet obesity expert who is not involved in the study, told CBS News.Dr. Ward expressed excitement about the potential benefits beyond weight loss, referencing human data that shows GLP-1 drugs improve diabetes risk and long-term health. “That’s why we’re so excited because when we look at, especially in cats, one of the biggest health threats is obesity and then diabetes,” he said.A veterinarian and diplomate of American College of Veterinary Preventive Medicine, Dr. Scott Willens, told the New York Sun that he would not discount the data or the use of GLP-1s on their face, particularly if a cat has diabetes or heart issues; however, most feline obesity is due to the behavior of the owner, not the animal.“It’s not a matter of will power … and they don’t have opposable thumbs” to open the cans of food themselves, Dr. Willens said. He added that owners should not leave food out for pets to graze all day but should set it out for brief periods twice a day and remove it afterward regardless of whether it is eaten. “They’re supposed to eat discrete meals twice a day, like lions on the Serengeti. There’s not supposed to be an all-you-can-eat buffet,” he said.OKAVA has said it is aiming for the treatment to cost owners around $100 per month.The MEOW-1 trial will evaluate the safety, tolerability, and efficacy of OKV-119 in 50 overweight or obese cats. Results are expected next summer, and the company hopes to seek FDA approval for use in cats within the next two years, with a similar study for dogs planned to follow.

‘Ozempic’ for Pets on the Horizon as New Drug Trial Aims To Tackle Feline Obesity

‘Ozempic’ for Pets on the Horizon as New Drug Trial Aims To Tackle Feline Obesity

More from the New York Sun

The Long Goodbye

Trump’s Pro-Life Legacy in the Balance

Trump: ‘America Belongs to Those Who Love It’

Israel Triggers Earthquake by Detonating Hezbollah Tunnel Network in Lebanon

Catholic Burnham Seeks Abolition of ‘Archaic Anomaly’ Barring Him From Ministerial Powers Over Church of England

Houthis Capture Key Red Sea Port as They March Toward Aden, Spiking Oil Prices

Anthropic Says It Discovered Scientists Using Its AI Models for Research That Could Create Bioweapons

Star Chemistry Saves ‘Practical Magic 2’ From Being Hocus Pocus

More from the New York Sun

The Long Goodbye

Trump’s Pro-Life Legacy in the Balance

Trump: ‘America Belongs to Those Who Love It’

Israel Triggers Earthquake by Detonating Hezbollah Tunnel Network in Lebanon

Catholic Burnham Seeks Abolition of ‘Archaic Anomaly’ Barring Him From Ministerial Powers Over Church of England

Houthis Capture Key Red Sea Port as They March Toward Aden, Spiking Oil Prices

Anthropic Says It Discovered Scientists Using Its AI Models for Research That Could Create Bioweapons

Star Chemistry Saves ‘Practical Magic 2’ From Being Hocus Pocus